✦ LIBER ✦

Development of a DNA-MVA/HIVA vaccine for Kenya

✍ Scribed by Tomáš Hanke; Andrew J McMichael; Matilu Mwau; Edmund G.-T Wee; Inese Ceberej; Sandip Patel; Julian Sutton; Maxine Tomlinson; Rachel V Samuel

Book ID: 117430868
Publisher: Elsevier Science
Year: 2002
Tongue: English
Weight: 45 KB
Volume: 20
Category: Article
ISSN: 0264-410X
DOI: 10.1016/s0264-410x(02)00085-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Development of a candidate DNA/MVA HIV-1

Development of a candidate DNA/MVA HIV-1 subtype C vaccine for India

✍ Sanjeev Kumar; Priya Aggarwal; Madhu Vajpayee; R.M. Pandey; Pradeep Seth 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 301 KB

Induction of long-lasting multi-specific

Induction of long-lasting multi-specific CD8+ T cells by a four-component DNA-MVA/HIVA-RENTA candidate HIV-1 vaccine in rhesus macaques

✍ Eung-Jun Im; Joseph P. Nkolola; Kati di Gleria; Andrew J. McMichael; Tomáš Hanke 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 613 KB

## Abstract As a part of a long‐term effort to develop vaccine against HIV‐1 clade A inducing protective T cell responses in humans, we run mutually complementing studies in humans and non‐human primates (NHP) with the aim to maximize vaccine immunogenicity. The candidate vaccine under development

Lessons from IAVI-006, a Phase I clinica

Lessons from IAVI-006, a Phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers

✍ A. Guimarães-Walker; N. Mackie; S. McCormack; T. Hanke; C. Schmidt; J. Gilmour; 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 498 KB

Engineering RENTA, a DNA prime-MVA boost

Engineering RENTA, a DNA prime-MVA boost HIV vaccine tailored for Eastern and Central Africa

✍ Nkolola, J P; Wee, EG-T; Im, E-J; Jewell, C P; Chen, N; Xu, X-N; McMichael, A J; 📂 Article 📅 2004 🏛 Nature Publishing Group 🌐 English ⚖ 619 KB

Corrigendum to “Lessons from IAVI-006, a

Corrigendum to “Lessons from IAVI-006, a Phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers” [Vaccine 26 (2008) 6671–6677]

✍ A. Guimarães-Walker; N. Mackie; S. McCormack; T. Hanke; C. Schmidt; J. Gilmour; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 91 KB

Use of apathogenic vaccinia virus MVA ex

Use of apathogenic vaccinia virus MVA expressing EHV-1 gC as basis of a combined recombinant MVA/DNA vaccination scheme

✍ Hartwig P. Huemer; Birgit Strobl; Norbert Nowotny 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 390 KB